SDHB (succinate dehydrogenase iron-sulfur subunit B) is a core catalytic component of mitochondrial Complex II, a unique respiratory complex that also functions as an enzyme of the tricarboxylic acid (TCA) cycle. By linking succinate oxidation to electron transfer into the ubiquinone pool, SDHB sits at a critical metabolic checkpoint for neuronal energy production, redox control, and signaling. Although SDHB is classically discussed in tumor predisposition syndromes, Complex II stress and succinate-driven signaling have growing relevance to neurodegeneration mechanisms.
Complex II is composed of SDHA/SDHB catalytic subunits and SDHC/SDHD membrane anchors. SDHB carries iron-sulfur clusters that relay electrons from SDHA (succinate oxidation) toward membrane-bound ubiquinone reduction.[1][2] This architecture makes SDHB essential for coupling the TCA cycle to respiratory-chain electron flow.
In neurons and glia, SDHB integrity supports:
When SDHB function declines, succinate can accumulate, respiratory output can drop, and oxidative stress plus inflammatory signaling can increase.[3][4]
SDHB dysfunction intersects with several pathways important in chronic neurodegenerative disease:
This framework connects SDHB/Complex II biology to broader mitochondrial dysfunction signatures seen in Alzheimer's disease, Parkinson's disease, and multisystem tauopathies where energetic reserve is limited.[3:3][5:3]
Pathogenic SDHB variants are well established in hereditary paraganglioma-pheochromocytoma syndromes, with disease risk linked to impaired succinate dehydrogenase function and pseudohypoxic signaling.[6:1][8] Primary neurodegenerative syndromes directly caused by SDHB are uncommon, but SDH pathway disruption offers a robust human model of mitochondrial-metabolic stress with CNS implications.[4:2][8:1]
In neurodegeneration research, SDHB is therefore relevant less as a single-disease marker and more as part of an integrated mitochondrial vulnerability network that includes Complex I deficits, altered NAD redox state, and impaired quality-control programs.[3:4][7:1]
Potential SDHB-related readouts in translational studies include:
These markers are most informative when interpreted in context with broader mitochondrial pathway features, rather than as isolated endpoints.
There is no approved therapy that directly rescues SDHB-specific deficits in neurodegeneration. Current strategy is pathway-oriented:
Future precision approaches may require stratifying patients by integrated mitochondrial-metabolic phenotypes rather than single-gene status alone.
Sun F, Huo X, Zhai Y, et al. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell. 2005. ↩︎ ↩︎
Cecchini G. [Function and structure of complex II of the respiratory chain](https://doi.org/10.1016/S0005-2728(03). Biochimica et Biophysica Acta. 2003. ↩︎ ↩︎
Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005. ↩︎ ↩︎ ↩︎ ↩︎
Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics. 2012. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Gill AJ. Succinate dehydrogenase (SDH)-deficient neoplasia. Histopathology. 2018. ↩︎ ↩︎ ↩︎
Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain. Free Radical Biology and Medicine. 2010. ↩︎ ↩︎ ↩︎
Fishbein L, Nathanson KL. Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Treatment Reviews. 2012. ↩︎ ↩︎
Beal MF. Mitochondria and neurodegeneration. Neuron. 2005. ↩︎
Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in brain aging and neurodegenerative disorders. Cell Metabolism. 2019. ↩︎